NO20006113D0 - Anvendelse av cyklosporiner i behandlingen av inflammatoriske autoimmune sykdommer - Google Patents

Anvendelse av cyklosporiner i behandlingen av inflammatoriske autoimmune sykdommer

Info

Publication number
NO20006113D0
NO20006113D0 NO20006113A NO20006113A NO20006113D0 NO 20006113 D0 NO20006113 D0 NO 20006113D0 NO 20006113 A NO20006113 A NO 20006113A NO 20006113 A NO20006113 A NO 20006113A NO 20006113 D0 NO20006113 D0 NO 20006113D0
Authority
NO
Norway
Prior art keywords
cyclosporins
treatment
autoimmune diseases
inflammatory autoimmune
inflammatory
Prior art date
Application number
NO20006113A
Other languages
English (en)
Other versions
NO20006113L (no
Inventor
Peter Hiestand
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20006113D0 publication Critical patent/NO20006113D0/no
Publication of NO20006113L publication Critical patent/NO20006113L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20006113A 1998-06-02 2000-12-01 Anvendelse av cyklosporiner i behandlingen av inflammatoriske autoimmune sykdommer NO20006113L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9811854.0A GB9811854D0 (en) 1998-06-02 1998-06-02 Organic compounds
PCT/EP1999/003770 WO1999062540A1 (en) 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Publications (2)

Publication Number Publication Date
NO20006113D0 true NO20006113D0 (no) 2000-12-01
NO20006113L NO20006113L (no) 2001-01-25

Family

ID=10833083

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006113A NO20006113L (no) 1998-06-02 2000-12-01 Anvendelse av cyklosporiner i behandlingen av inflammatoriske autoimmune sykdommer

Country Status (17)

Country Link
EP (1) EP1082130A1 (no)
JP (2) JP4523154B2 (no)
KR (1) KR20010043969A (no)
CN (1) CN1304315A (no)
AU (1) AU750422B2 (no)
BR (1) BR9910860A (no)
CA (1) CA2333315A1 (no)
GB (1) GB9811854D0 (no)
HU (1) HUP0102142A3 (no)
ID (1) ID27576A (no)
IL (1) IL139589A0 (no)
NO (1) NO20006113L (no)
PL (1) PL344451A1 (no)
SK (1) SK18142000A3 (no)
TW (2) TWI250021B (no)
WO (1) WO1999062540A1 (no)
ZA (1) ZA200006464B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030379A2 (en) 1999-10-27 2001-05-03 Alexandra Lucas Compositions and methods for preventing and treating transplant rejection
JP2004509171A (ja) * 2000-09-29 2004-03-25 ゾーン、　ロバート　ズィー． 炎症及び免疫反応の治療方法及びその組成物
JP2006524232A (ja) 2003-03-17 2006-10-26 アルバニー モレキュラー リサーチ インコーポレーティッド 新規サイクロスポリン
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
EP1742652A2 (en) * 2004-04-08 2007-01-17 Novartis AG Use of cyclosporins for treatment of cerebral ischemia and brain and spinal cord injury
BRPI0513370A (pt) 2004-07-14 2008-05-06 Novartis Ag uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
JP2008514701A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
EP1804823A4 (en) 2004-09-29 2010-06-09 Amr Technology Inc NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS
UA88484C2 (ru) * 2004-10-01 2009-10-26 Дебиофарм Са ПРИМЕНЕНИЕ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИНА ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИИ ГЕПАТИТА С И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ВКЛЮЧАЕТ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИН
US7361636B2 (en) 2004-10-06 2008-04-22 Amr Technology, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
WO2006071618A1 (en) * 2004-12-23 2006-07-06 Novartis Ag Compounds for flaviviridae treatment
CA2587793A1 (en) * 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment
AR054778A1 (es) * 2005-06-17 2007-07-18 Novartis Ag Uso de sangliferina en hcv
JP2007112775A (ja) * 2005-10-24 2007-05-10 Hamamatsu Univ School Of Medicine サイトメガロウイルス感染の処置におけるシクロスポリン類の使用
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
EP2376524B1 (en) 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
US20110144005A1 (en) * 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
WO2014049540A2 (en) 2012-09-29 2014-04-03 Novartis Ag Cyclic peptides and use as medicines
CN104870007A (zh) * 2012-10-19 2015-08-26 西尼克斯公司 新的抗病毒大环化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE148469T1 (de) * 1990-11-02 1997-02-15 Sandoz Ag Zyklosporine
AR006514A1 (es) * 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
CZ288739B6 (cs) * 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky

Also Published As

Publication number Publication date
TW200522975A (en) 2005-07-16
CA2333315A1 (en) 1999-12-09
KR20010043969A (ko) 2001-05-25
WO1999062540A1 (en) 1999-12-09
TWI250021B (en) 2006-03-01
IL139589A0 (en) 2002-02-10
AU4372499A (en) 1999-12-20
NO20006113L (no) 2001-01-25
TWI250022B (en) 2006-03-01
ZA200006464B (en) 2002-03-11
SK18142000A3 (sk) 2001-06-11
HUP0102142A2 (hu) 2001-11-28
BR9910860A (pt) 2001-03-06
HUP0102142A3 (en) 2001-12-28
JP2010059177A (ja) 2010-03-18
EP1082130A1 (en) 2001-03-14
AU750422B2 (en) 2002-07-18
JP2002516873A (ja) 2002-06-11
JP4523154B2 (ja) 2010-08-11
PL344451A1 (en) 2001-11-05
ID27576A (id) 2001-04-12
CN1304315A (zh) 2001-07-18
GB9811854D0 (en) 1998-07-29

Similar Documents

Publication Publication Date Title
NO20006113L (no) Anvendelse av cyklosporiner i behandlingen av inflammatoriske autoimmune sykdommer
PT1028954E (pt) Imidazoles substituidos uteis no tratamento de doencas inflamatorias
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
ZA983452B (en) Substituted pyrrolopyridines useful in the treatment of inflammatory diseases.
IL133766A0 (en) 2-substituted imidazoles useful in the treatment of inflammatory diseases
PL348059A1 (en) Compounds useful in the treatment of inflammatory diseases
PL362984A1 (en) Compounds useful in the treatment of inflammatory diseases
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
DE69930165D1 (de) Humanes delta 5-desaturase-gen
EE03512B1 (et) Epinastiin kasutamiseks valude ravis
EE200300214A (et) Sulfoonamiidid endoteliini vahendatud haiguste ravimiseks
PT946175E (pt) Utilizacao de uma combinacao de inibidores de h+, k+ -atpase e de glucocorticiodes no tratamento de polipos nasais
ZA984174B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
NO20031525L (no) Kjemokinmutanter i behandlingen av multippel sklerose
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
IL133089A0 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
EP1027007A4 (en) Dental treatment methods
EP1224201A4 (en) 32 HUMAN SECRETED PROTEINS
ID30458A (id) Osanetan dalam pengobatan gangguan jiwa
NO20010044L (no) Anvendelse av texafyriner i makrofag-medierte sykdommer
HUP0200354A3 (en) Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
NO20030762D0 (no) Forbedret spesifisitet i behandling av sykdommer
DK5198A (da) Endoskopisk Dormia-fremmedlegemeekstraktor
AU2002300624A1 (en) Substituted imidazoles useful in the treatment of inflammatory diseases
IT1311913B1 (it) Impiego di 6-metilmercaptopurina riboside in composizionioftalmologiche.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application